



Web App ASSIST Report

Substance Use Screenings Across South Africa (January to June 2025)

The South African Community Epidemiology Network on Drug Use (SACENDU), October/November 2025

Ayanda Mkhize, Shaheema Allie, and A/Prof Goodman Sibeko

Division of Addiction Psychiatry, University of Cape Town



Overview





SACENDU SOUTH AFRICAN COMMUNITY EPIDEMIOLOGY NETWORK ON DRUG USE

Treatment Demand Data • Service Quality Measures (SQM) • Community-Based Harm Reduction Services

ASSIST Intro

January to June 2025 Reach

Report

Key findings and recommendati ons





What is the ASSIST


...and what is the Web App



WHO ASSIST (Alcohol, Smoking and Substance

Involvement Screening Test)





A. WHO - ASSIST V3.0

treated as strictly confidential

INTERVIEWER ID		Country		CLINIC		
PATIENT ID			DATE			
Introduction (I	Please read to paties	nt)				
drugs. I am goi your lifetime an	ng to ask you some d in the past three i	t in this brief interview abo questions about your expe months. These substances rm of pills (show drug card)	rience of us can be smo	sing these :	substano	es across
medications). For doctor. However,	or this interview, we er, if you have taken	be prescribed by a doctor (I e will <u>not</u> record medication n such medications for reas than prescribed, please let	ns that are i ons <u>other</u> ti	used <u>as pr</u> han prescr	escribed iption, or	by your taken thei

NOTE: BEFORE ASKING QUESTIONS, GIVE ASSIST RESPONSE CARD TO PATIENT

Question 1 if completing follow-up please cross check the patient's answers with the answers given for Q1 a becaling. Any differences on this question should be question.

In your life, which of the following substances have you ever used? (NON-MEDICAL USE ONLY)	No	Yes
a. Tobacco products (cigarettes, chewing tobacco, cigars, etc.)	0	3
b. Alcoholic beverages (beer, wine, spirits, etc.)	0	3
c. Cannabis (marijuana, pot, grass, hash, etc.)	0	3
d. Cocaine (coke, crack, etc.)	0	3
e. Amphetamine type stimulants (speed, diet pills, ecstasy, etc.)	0	3
f. Inhalants (nitrous, glue, petrol, paint thinner, etc.)	0	3
g. Sedatives or Sleeping Pills (Valium, Serepax, Rohypnol, etc.)	0	3
h. Hallucinogens (LSD, acid, mushrooms, PCP, Special K, etc.)	0	3
i. Opioids (heroin, morphine, methadone, codeine, etc.)	0	3
j. Other - specify:	0	3

Probe if all answers are negative:
"Not even when you were in school?"
"It "les" to any of these items, ask Question 2 for each substance ever used.

- Asks about recent substance use over the past 3 months and assesses for lifetime use risks.
- Comprehensive list of substances is long and includes tobacco and alcohol.
- Provides a level of risk for each substance.
- Second part of the tool provides information for Brief Intervention (BI) component.
 - Information and feedback about the risks and harms associated for each substance.
 - Covers physical, medical, and psychological risks of regular substance use.
- High risk screening scores will lead to further assessment and a referral to specialized treatment.
 Usually a small proportion (5%) of the using population will be at high risk. The rest of the individuals can be treated via a BI.



WebApp ASSIST


https://assistscreening.uct.ac.za




- Anonymized
 - No personal identifying data included in general structure. This can be modified for specific purposes
- Random code generated with each screening process
- Any device
- Data-light
- Automated
- Reduces training burden
- Screening report and intervention recommendation can be screenshot or emailed, following which the email entered for receipt is not stored on the system













Web App benefits



Standardized screening

Early detection and prevention

Supports datadriven intervention strategies.


Passive risk mapping





Web App ASSIST Pathways









January to June 2025 data

What was the reach?






January to June 2025











Report: January to June 2025


Report covers demographics, risk levels, and substance use patterns.





Participant Demographics






Genders: Female, Male, Transgender, and Prefer not to say.

(Future reports will include breakdown)






Screening Pathways & National Results South Africa





Total Screenings by Province










Risk level summary












General risk profile per province









Key Findings



Key Findings 1/2



Moderate risk was most common across provinces.

Mpumalanga recorded the highest screening numbers

- High Risk Substances: Alcohol, Inhalants, Cannabis, Tobacco
- Moderate Risk Substances: Alcohol, Cannabis, Cocaine, Nyaope, Meth, Hookah, etc.
- Low Risk Substances: Inhalants, Meth, Opioids, Tobacco, Vape
- High-risk screenings mainly among children in Mpumalanga (n=14);



Key Findings 2/2



Alcohol, Cannabis, and Tobacco were the most reported substances.

Practitioner-led screenings found more high-risk cases.

Gauteng

• All self-screenings, 1 high-risk for Cocaine

Northern Cape

• Moderate risk dominant (119), no high risk


Western Cape

• No high risk; moderate risk includes Cannabis, Tobacco

KwaZulu-Natal

• 2 high-risk; Cocaine, Stimulants





Expanded Key Findings



1,483 screenings nationally

• 81% practitioner-led, 19% self-screenings.

Moderate risk most prevalent (736; approximately 50%).

High-risk cases (18) concentrated among children aged 10-14 in Mpumalanga.

Practitioner screenings identified more high-risk users than self-screenings.

Alcohol, Cannabis, and Tobacco most reported; emerging use of vapes, meth, sedatives noted.



Provincial Insights



Mpumalanga:

Highest screenings (518) and all child high-risk cases.

Gauteng & Northern Cape:

Moderate alcohol and stimulant use common.

Western Cape & KZN:

No child high-risk cases, but moderate adult use evident.

Limpopo & North West:

• Low-risk but increasing stimulant exposure.

Variations may reflect local prevention programs and reporting rates.



Summary & Recommendations



Noteworthy

- Mpumalanga: Urgent need for early intervention in children
- High prevalence of alcohol and stimulant use across provinces

Recommendations

- Strengthen youth-focused prevention programs.
- Expand early intervention in high-risk provinces.
- Increase practitioner training for early risk detection.
- Integrated SBIRT in schools and clinics
- Province-specific substance use interventions
- Integrate screening data with national health strategies for policy response.
- Adult moderate-risk prevalence highlights prevention opportunities











goodman.sibeko@uct.ac.za



https://sudservices.uct.ac.za

https://assistscreening.uct.ac.za

http://www.psychiatry.uct.ac.za/psych/addiction-psychiatry



